Bars

S2-E54.3 – Inside the Patient-Focused Drug Development Meeting: The Advocates’ Priorities

S2-E54.3 - Inside the Patient-Focused Drug Development Meeting: the Advocates' Priorities
Global Liver Institute Founder, President and CEO Donna Cryer and her fellow patient and patient advocate Terri Milton join Stephen Harrison, Louise Campbell and Roger Green. They discussed the ground-breaking NASH Patient-Focused Drug Development meeting held on November 4, 2021. This included the advocates' priorities (both those who spoke in the PFDD session and others like our panelists) for changes in regulatory policy and programs.

In this conversation, the Surfers and the patient/patient advocate guests share divergent opinions about the relative value of drug development vs. support for non-invasive testing as the top advocacy priority. The group wraps up the episode (and this conversation) by discussing the one message each person hopes regulators took from the Patient-Focused Drug Development meeting.

The NASH Tsunami In Diabetes

Categories for NASH Tsunami
Allied Health Professionals Cirrhosis Clinical Trials Companies COVID-19 Diabetes Diagnostics Digital Health Digital Therapeutics Doctors Drugs/Drug Classes Drug therapies Endocrinology clinics Epidemiology Fatty Liver FDA FIB-4 GLP-1s Guidelines Hepatology Histopathology Inside The Vault Investors Liver Science Major Meetings Metabolic Diseases Motivating front-line treaters NAFLD NAFLD Prevalence NAIL-NIT NASH NASH-TAG NASH/Diabetes Co-Morbidity NITs Obesity Patient Advocacy Patients Pediatric NASH Podcast Prevalence/Incidence Public Health Rising Tide Special Subpopulations Suggested Reading Type 2 Diabetes Mellitus

Listen Now

Apple Spotify Youtube
Copyright © SurfingNASH.Com 2020—2023
Linkedin Facebook Twitter Instagram
Apple Spotify Youtube Soundcloud
More Episodes
Log In
Stay In Touch
Apple Spotify Youtube

Experience Nudge Learning! Interested in a new way of learning?

Learn More About CME